Trial Condition(s):
Primovist: DDI with OATP-Inhibitor
13358
Not Available
Not Available
Please see attached Study Results Summary below
No Inclusion Criteria Available
No Exclusion Criteria Available
Locations | Status | |
---|---|---|
Locations Bayer Schering Pharma AG Berlin, Germany, 13353 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |